--- title: 'Zepbound vs Wegovy Side Effects: What to Expect and How to Track Them' date: '2026-06-21' slug: zepbound-vs-wegovy-side-effects-what-to-expect-and-how-to-track-them description: Compare Zepbound and Wegovy side effects, learn common symptoms, duration, and how to log them with a GLP‑1 tracker like Pepio. Get practical tips for tracking nausea, appetite changes, and more. updated: '2026-06-21' image: https://images.unsplash.com/photo-1638730647755-1bf55b465e67?crop=entropy&cs=tinysrgb&fit=max&fm=jpg&ixid=M3w1NDkxOTh8MHwxfHNlYXJjaHwzfHwlN0IlMjdrZXl3b3JkJTI3JTNBJTIwJTI3emVwYm91bmQlMjB2cyUyMHdlZ292eSUyMHNpZGUlMjBlZmZlY3RzJTI3JTJDJTIwJTI3dHlwZSUyNyUzQSUyMCUyN2NvbXBhcmlzb24lMjclMkMlMjAlMjdzZWFyY2hfaW50ZW50JTI3JTNBJTIwJTI3Y29tcGFyZSUyMHRoZSUyMHNpZGUlMjBlZmZlY3QlMjBwcm9maWxlcyUyMG9mJTIwWmVwYm91bmQlMjBhbmQlMjBXZWdvdnklMjclMkMlMjAlMjdleGFtcGxlX3F1ZXJ5JTI3JTNBJTIwJTI3WmVwYm91bmQlMjB2cyUyMFdlZ292eSUyMHNpZGUlMjBlZmZlY3RzJTIwY29tcGFyaXNvbiUyNyU3RHxlbnwwfHx8fDE3ODIwMDA3NTJ8MA&ixlib=rb-4.1.0&q=80&w=400 author: Dr. Benjamin Paul site: 'Pepio: GLP-1 Peptide Tracker' --- # Zepbound vs Wegovy Side Effects: What to Expect and How to Track Them ## Zepbound vs Wegovy Side Effects: Why Comparing Matters A Zepbound vs Wegovy side effects comparison overview helps anyone managing a GLP‑1 routine. Wegovy (semaglutide) is a GLP‑1 receptor agonist and Zepbound (tirzepatide) is a dual GIP/GLP‑1 receptor agonist; both have overlapping gastrointestinal side effects, but incidence and patient experience can differ. In a [head‑to‑head trial](https://investor.lilly.com/news-releases/news-release-details/zepbound-tirzepatide-showed-superior-weight-loss-over-wegovy), tirzepatide showed greater average weight loss than semaglutide at 72 weeks. Clinical data also show both drugs report similar GI events, though rates vary across doses and studies ([Zepbound clinical data](https://zepbound.lilly.com/hcp/clinical-data-weight)). Pepio helps you track side effects for both GLP‑1 and dual‑incretin therapies in one place. **Tracking side effects** helps you spot patterns, stay consistent, and prepare clearer notes for clinicians. Pepio helps you keep that record in one place and organize dose histories before appointments. This section previews comparison criteria, practical tracking tips, and a clear view of common side effects. ## How to Compare GLP‑1 Side‑Effect Profiles If you’re wondering how to compare GLP‑1 side‑effect profiles, focus on five clear dimensions. Symptom type, timing, duration, severity, and daily‑life impact give you a practical framework. GLP‑1 receptor agonists share core gastrointestinal effects like nausea, vomiting, constipation, and diarrhea, but incidence and timing vary by drug and dose ([NCBI Bookshelf](https://www.ncbi.nlm.nih.gov/books/NBK572151/)). Clinical and safety reviews of tirzepatide highlight different adverse‑event patterns compared with other GLP‑1s, so comparing metrics matters for real users ([PMC article](https://pmc.ncbi.nlm.nih.gov/articles/PMC9915969/)). Tracking these five dimensions helps you see whether side effects appear right after a shot or only after a dose increase. Pepio helps you keep those comparisons in one place so you can review trends without digging through notes. Use simple, consistent fields when you log: the symptom, when it started, how long it lasted, how bad it felt, and whether it changed your appetite or daily activities. That consistency makes it easier to compare one medication or titration step to the next. # - Onset timing (hours vs days) — Example: nausea often starts within 3–7 days, so check daily notes in week one ([NCBI Bookshelf](https://www.ncbi.nlm.nih.gov/books/NBK572151/)). - Typical duration (short‑term vs persistent) — Example: brief nausea that fades after titration needs different follow‑up than persistent symptoms. - Severity scale (mild, moderate, severe) — Example: rate how much a symptom limits eating or activity to spot patterns. - Effect on appetite and food noise — Example: note whether appetite drops or cravings return after a dose change. Use Pepio to log these fields consistently so you can compare profiles over time and bring organized notes to your clinician. ## Pepio GLP‑1 Tracker: Your Best Tool for Monitoring Zepbound and Wegovy Side Effects Pepio consolidates the practical pieces of a GLP‑1 routine so you can watch side effects without juggling notes. Pepio unifies dose logs, injection‑site rotation, symptom notes (where you can include appetite/food‑noise details), weight tracking, and reminders in one record. Pepio’s web tools are free with no sign‑up and store data in your browser; the iOS app (free to download) adds push notifications and PDF export. That single record makes it easier to see whether nausea, appetite changes, or fatigue show up after a specific shot. Pepio also offers exportable reports and free web calculators for conversions and vial math, so you can prepare cleaner notes for clinician visits and plan refills without guesswork ([Pepio GLP‑1 Tracker on the App Store](https://apps.apple.com/us/app/glp-1-tracker-pep/id6504788281)). Nausea and other side effects vary by medication and dose. Public comparisons show nausea appears more often with Wegovy than with Zepbound, which may affect what you track and when to check in with your clinician ([GoodRx comparison of Zepbound vs. Wegovy](https://www.goodrx.com/conditions/weight-loss/zepbound-vs-wegovy)). Using a single, consistent log makes those differences easier to spot over weeks. Users who choose Pepio get one place to keep daily notes and a clear export to bring to appointments ([Pepio GLP‑1 Tracker on the App Store](https://apps.apple.com/us/app/glp-1-tracker-pep/id6504788281)). # - Single source of truth eliminates scattered screenshots — keeps your dose history, site notes, and symptom entries together for quick review. - Trend charts reveal patterns over weeks — visual trends help you spot recurring nausea, appetite dips, or food‑noise changes. - Secure export simplifies doctor appointments — organized reports let you share dose history and symptom timelines with your clinician. # - No automated dosing recommendations — Pepio helps you record the dose your clinician prescribed; it does not suggest changes. - Requires consistent user entry — the tracker works best when you log shots, symptoms, and weight regularly. - Not a substitute for clinician advice — use your exported notes to inform conversations, not to replace medical guidance. Tracking side effects for Zepbound versus Wegovy often comes down to consistent notes and clear timelines. Pepio's focus on dose history, site rotation, symptom categories, and exportable reports makes it a practical first choice for users who want organized side‑effect records. Learn more about Pepio's approach to side‑effect tracking and see how it can help you keep dose history, symptom logs, and weight progress in one place. Pepio is for organization and self‑tracking only. Pepio does not provide medical advice, diagnosis, treatment, dosing recommendations, or protocol recommendations. Always follow instructions from your clinician, prescriber, pharmacist, or medication label. ## Zepbound Side Effects: What to Expect and Track Zepbound commonly causes gastrointestinal side effects. Trial summaries report nausea in about 30% of users, diarrhea in about 20%, and constipation near 15% ([Healthline](https://www.healthline.com/health/drugs/zepbound-side-effects)). Injection-site reactions such as pain, redness, or swelling occurred in roughly 5–7% of participants ([FDA prescribing information](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217806s003lbl.pdf)). Serious adverse events are rare; pancreatitis is uncommon, and gallbladder‑related events can occur and vary by dose ([PMC 2025](https://pmc.ncbi.nlm.nih.gov/articles/PMC12469573/); [PMC 2023](https://pmc.ncbi.nlm.nih.gov/articles/PMC9915969/)). Pepio can help you correlate symptom timing with specific doses and keep a clear record for clinician review. - Nausea — reported by roughly 30% in trials; often appears within the first week - Diarrhea — ~20% incidence across Phase 3 tirzepatide trials - Constipation — ~15% reported in SURPASS trials - Injection‑site reactions — 5–7% (pain, redness, swelling) - Serious adverse events (pancreatitis, gallbladder disease) — serious adverse events are rare; pancreatitis is uncommon, and gallbladder‑related events can occur and vary by dose Symptoms often start soon after treatment begins. Nausea tends to appear early and then lessen for many people over several weeks ([Healthline](https://www.healthline.com/health/drugs/zepbound-side-effects)). Rare serious events were flagged in both controlled trials and post‑marketing reviews; documenting onset and severity helps clinicians evaluate events ([PMC 2023](https://pmc.ncbi.nlm.nih.gov/articles/PMC9915969/); [PMC 2025](https://pmc.ncbi.nlm.nih.gov/articles/PMC12469573/)). What to record in your symptom log: - Timing — when the symptom started relative to your shot - Severity — mild, moderate, or severe (your words) - Duration — how long the symptom lasted - Appetite/food‑noise notes — changes in hunger, cravings, or fullness Keep your notes organized so you can spot patterns and bring clear details to follow‑ups. Pepio helps you keep a clean symptom timeline and record timing, severity, and appetite changes without replacing clinical advice. People using Pepio report clearer dose and symptom histories to share with their clinicians. Learn more about Pepio’s approach to symptom tracking to prepare better notes for appointments. Pepio is for organization and self‑tracking only. It does not provide medical advice, dosing recommendations, or clinical guidance. Contact your clinician for concerning or persistent symptoms. Common Wegovy side effects include nausea (reported around the low‑to‑mid 40% range in some trial summaries), variable rates of diarrhea and vomiting, and injection‑site reactions. Injection‑site reactions occur in both medications and vary by study and dose ([Lilly Press Release](https://investor.lilly.com/news-releases/news-release-details/zepbound-tirzepatide-showed-superior-weight-loss-over-wegovy); [NCBI Bookshelf](https://www.ncbi.nlm.nih.gov/books/NBK572151/)). Nausea typically appears in the first week and often eases by week four during slow titration. Nursing analyses and trial summaries offer useful timing context when you compare side‑effect patterns ([NCBI Bookshelf](https://www.ncbi.nlm.nih.gov/books/NBK572151/); [University of Pennsylvania](https://www.nursing.upenn.edu/live/news/3213-study-suggests-a-new-drug-for-weight-loss-may)). When you log Wegovy side effects, include: - Nausea — reported in trial summaries at rates around the low-to-mid 40% range (varies by dose) - Diarrhea and vomiting — incidence varies across studies; vomiting generally less common than nausea - Injection‑site reactions — occur with both medications and vary by study and dose - Impact on appetite/food noise — commonly reported, track appetite and cravings alongside weight Pepio helps you keep these notes organized so you can compare your Wegovy experience to Zepbound or other options. Pepio is for organization and self‑tracking only and does not provide medical advice. Always follow instructions from your clinician, prescriber, pharmacist, or medication label. Head‑to‑head trials show tirzepatide produced larger average weight loss than semaglutide in SURMOUNT‑5 for obesity; note that SURPASS‑2 was a head‑to‑head trial in people with type 2 diabetes. Gastrointestinal effects, especially nausea, were common; obesity trials report nausea rates for tirzepatide in the roughly ~20–33% range (and tended to be lower in some type 2 diabetes trials), consistent with the earlier ~30% figure in broader summaries ([Adverse Events Related to Tirzepatide](https://pmc.ncbi.nlm.nih.gov/articles/PMC9915969/); [UPenn nursing study](https://www.nursing.upenn.edu/live/news/3213-study-suggests-a-new-drug-for-weight-loss-may)). Injection‑site reaction rates differed modestly between studies, according to trial safety tables ([Zepbound Clinical Data](https://zepbound.lilly.com/hcp/clinical-data-weight)). Real‑world surveillance also suggests lower discontinuation with tirzepatide in some datasets ([Real‑World Safety Concerns](https://pmc.ncbi.nlm.nih.gov/articles/PMC12469573/)). For everyday tracking, prioritize percent weight change, timing and severity of GI symptoms, and injection‑site notes. Users using Pepio can log dose dates, symptom severity, and site rotation to reveal patterns over weeks. Pepio's approach to concise logs helps you prepare clearer notes for follow‑ups. Learn more about Pepio's approach to tracking side effects and organizing your routine before your next clinician visit. Use this checklist after each shot to compare side effects between Zepbound and Wegovy. Timing and symptom patterns can differ across GLP-1 receptor agonists ([NCBI Bookshelf](https://www.ncbi.nlm.nih.gov/books/NBK572151/)). - Log dose date/time and injection site every shot - Record symptoms with onset time, severity (mild/moderate/severe), and duration - Note appetite/food-noise changes and any missed doses - Weigh in consistently and record percentage weight change over time - Export or summarize trends before clinician visits Check in daily during titration weeks for new or changing doses. During maintenance, weekly or biweekly check-ins usually suffice. Look for symptom timing tied to shot day, dose changes, or missed shots. Summarize trends as short bullet points for clinician visits. Pepio helps keep those summaries and logs in one place for clearer follow-ups ([Pepio GLP‑1 Tracker – Apple App Store](https://apps.apple.com/us/app/glp-1-tracker-pep/id6504788281)). Users using Pepio often find patterns faster and save time when sharing notes. Pepio is for organization and self-tracking only. Follow your clinician, prescriber, pharmacist, or medication label for dosing and treatment decisions. Contact your clinician for severe or persistent symptoms. Seek care for intense abdominal pain, ongoing vomiting, or jaundice. These signs are noted in the [FDA prescribing information](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217806s003lbl.pdf). Real-world reviews urge reporting unusual or worsening side effects ([PMC analysis](https://pmc.ncbi.nlm.nih.gov/articles/PMC12469573/)). Pepio helps you record events for clinician visits, but it is for organization only. **Q: How can I track Zepbound side effects in a GLP‑1 tracker?** A: Log dose date/time, symptom type, onset and duration, severity, injection site, and appetite or food‑noise notes. Pepio helps keep those entries organized for trend review and sharing. Trials report gastrointestinal events with tirzepatide; record timing and severity for clinician discussions. **Q: What are the common side effects of Wegovy and how long do they last?** A: Common effects include nausea, diarrhea, and occasional vomiting. Nausea often begins within the first week and many people report improvement by week four during dose titration ([NCBI Bookshelf – Compare and Contrast the GLP‑1 Receptor Agonists](https://www.ncbi.nlm.nih.gov/books/NBK572151/)). Track onset and resolution dates, and notify your clinician if symptoms persist or worsen. **Q: How do Zepbound and Wegovy differ for nausea and appetite changes?** A: Both can cause nausea and appetite changes. Head‑to‑head trial data show weight‑loss differences (e.g., SURMOUNT‑5) and nausea rates that vary by dose and study. People using Pepio can compare timing, severity, and appetite changes to spot personal patterns and share trends with their clinician. Tracking side effects helps you compare personal experiences on Zepbound and Wegovy and reveal patterns over time. Learn Pepio's approach to tracking GLP‑1 side effects and try the app ([Pepio GLP‑1 Tracker – Apple App Store](https://apps.apple.com/us/app/glp-1-tracker-pep/id6504788281)). See the FDA prescribing information for Zepbound for clinical context ([FDA Prescribing Information – Zepbound (tirzepatide)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217806s003lbl.pdf)). Pepio is for organization and self‑tracking only and does not provide medical advice or dosing recommendations.